Starting on 29 May 2013 with many Oral Sessions fresh updates on Stroke Large clinical trials (RCTs)
at 11:25-12:30 Room: Auditorium INTERACT2, STICH II, CHIMES, IST-3, SPS3, next day PC-Trial, RESPECT, ALIAS, PHANTOM-S, ICSS, EVA-3S, STICH II.
The annual national Italian stroke survey was published on a large diffusion journal (FOCUS) inclusion criteria >50 stroke patients admitted per year in 2011. Markers of performance mortality a 1-month, re-admission in the month following the discharge for a stroke. Data as usual available from the national health care authorities.
Mortality rates in 2011 was 11.6 and re admission 10.62 (the best Italian centres had 2.73 and 7.31).
Boehringer in end 2012 announced the approval in 15 European countries with the mutual recognition procedure, the extent of window treatment with alteplase, rt-PA in cases of acute ischemic stroke within 4 hours of symptom onset and after have ruled out the diagnosis of intracranial hemorrhage. The completion of the regulatory process has been reported by Germany, the Reference Member State, and will allow the implementation of this approval also to the European Union member states that adhere to the mutual recognition procedure. Alteplase is indicated for the fibrinolytic treatment of acute ischemic stroke, or for the dissolution of the clot that has blocked artery, helping to restore the normal blood flow, preventing or limiting damage to ischemic brain tissue. To achieve the greatest possible benefits, treatment should be initiated as early as possible after symptom onset. Alteplase was approved in 1987 for various indications in many countries, and since 1996 for the treatment of ischemic stroke with administration within three hours of the onset of symptoms. The combined analysis of the results of different studies, with placebo control group, showed that treatment with rt-PA within 180 minutes after the onset of ischemic symptoms allows more likely to residuare 30% in less than disability arising from ischemic damage compared to untreated patients or little or no disability after three months of the event compared to patients who did not receive thrombolytic therapy. An official statement by the Italian regulatory agency is likely to be soon released in early 2013. For many Italian hospitals until the official statement of the agency the use of alteplase will not be considered fully appropriate
A survey by the Corriere della Sera on the so-called “Zamboni method” for the treatment of multiple sclerosis has evoked many reactions. Professor Giancarlo Comi, President of the Italian Society of Neurology clarifies his point of view on the matters in controversy, noting that the data currently available suggest that the assumptions underlying the method (which is the unblocking of the jugular veins intravascularly) not have sufficient basis
Senator Mark Kirk on his rehabilitation “walking program” – YouTube. top rehab made in Chicago
via Epidemiology of stroke in Maputo, Mozambique.
The chance to offer a low cost alternative to acute ischemic stroke may bring new interest on Strptokinase.
The wide availability of this drug for cardiological units may offer an great opportunity. A need for a restriction of the indication is the main countermeasure to adopt. On the International Stroke Journal you can read a deeper analysis of the topic.
The WordPress.com stats helper monkeys prepared a 2012 annual report for this blog.
Here’s an excerpt:
The new Boeing 787 Dreamliner can carry about 250 passengers. This blog was viewed about 1,500 times in 2012. If it were a Dreamliner, it would take about 6 trips to carry that many people.
May anti depressants be helpfull in stroke recovery ? also in non depressed subjects ?
Double blind placebo controlled on benefit of prolonged release Levomilnacipran in ischemic stroke recovery. A phase II RCT sponsored by Pierre Fabre Medicament IRPF. First patient enrolled in France. Up to 90 participating centres, six Italian centres will join the project. Stay tuned.
Cardioembolic Stroke as one of the leading cause of global disability deserves much more attention from health care authorities, the world stroke organization promotes the suscription of the “world stroke charter”
a signature may save lives
……We call on national governments, policy makers, payers and healthcare providers to take action to improve the lives of those with AF and drastically reduce the risks and costs of AF-related stroke.
Next week will take place in Sweden the annual meeting of the EFNS. This will be a chance to remember the pioneering work in the field of valsular neurology of Gösta Hultquist that in 1942 with his dissertation ”Über Thrombose und Embolie der Arteria carotis und hierbei vorkommende Gehirnveränderungen. Pathologisch-Anatomische Studie” TIA and symptomatic carotid stenosis were described and studied by the doctors of the Department of Pathology at St. Göran’s Hospital in Stockholm.
